LYRA
Price
$8.22
Change
-$0.31 (-3.63%)
Updated
Jul 18, 01:44 PM (EDT)
Capitalization
13.67M
25 days until earnings call
SQZB
Price
$0.03
Change
-$0.00 (-0.00%)
Updated
Jul 14 closing price
Capitalization
825.75K
21 days until earnings call
Interact to see
Advertisement

LYRA vs SQZB

Header iconLYRA vs SQZB Comparison
Open Charts LYRA vs SQZBBanner chart's image
Lyra Therapeutics
Price$8.22
Change-$0.31 (-3.63%)
Volume$100
Capitalization13.67M
SQZ Biotechnologies
Price$0.03
Change-$0.00 (-0.00%)
Volume$750
Capitalization825.75K
LYRA vs SQZB Comparison Chart in %
Loading...
LYRA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SQZB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
LYRA vs. SQZB commentary
Jul 18, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is LYRA is a Hold and SQZB is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 18, 2025
Stock price -- (LYRA: $8.55 vs. SQZB: $0.03)
Brand notoriety: LYRA and SQZB are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: LYRA: 3% vs. SQZB: 3%
Market capitalization -- LYRA: $13.67M vs. SQZB: $825.75K
LYRA [@Biotechnology] is valued at $13.67M. SQZB’s [@Biotechnology] market capitalization is $825.75K. The market cap for tickers in the [@Biotechnology] industry ranges from $299.62B to $0. The average market capitalization across the [@Biotechnology] industry is $2.46B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

LYRA’s FA Score shows that 0 FA rating(s) are green whileSQZB’s FA Score has 1 green FA rating(s).

  • LYRA’s FA Score: 0 green, 5 red.
  • SQZB’s FA Score: 1 green, 4 red.
According to our system of comparison, LYRA is a better buy in the long-term than SQZB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

LYRA’s TA Score shows that 3 TA indicator(s) are bullish while SQZB’s TA Score has 2 bullish TA indicator(s).

  • LYRA’s TA Score: 3 bullish, 4 bearish.
  • SQZB’s TA Score: 2 bullish, 2 bearish.
According to our system of comparison, SQZB is a better buy in the short-term than LYRA.

Price Growth

LYRA (@Biotechnology) experienced а -5.63% price change this week, while SQZB (@Biotechnology) price change was 0.00% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +3.34%. For the same industry, the average monthly price growth was +13.98%, and the average quarterly price growth was +35.39%.

Reported Earning Dates

LYRA is expected to report earnings on Aug 12, 2025.

SQZB is expected to report earnings on Aug 08, 2025.

Industries' Descriptions

@Biotechnology (+3.34% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
LYRA($13.7M) has a higher market cap than SQZB($826K). SQZB YTD gains are higher at: -6.667 vs. LYRA (-17.151).
LYRASQZBLYRA / SQZB
Capitalization13.7M826K1,659%
EBITDA-44.7MN/A-
Gain YTD-17.151-6.667257%
P/E RatioN/AN/A-
Revenue1.19MN/A-
Total Cash31.7MN/A-
Total Debt33.4MN/A-
TECHNICAL ANALYSIS
Technical Analysis
LYRASQZB
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
77%
N/A
Momentum
ODDS (%)
N/A
Bullish Trend 2 days ago
78%
MACD
ODDS (%)
N/A
Bullish Trend 2 days ago
81%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
80%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
75%
Advances
ODDS (%)
Bullish Trend 2 days ago
81%
N/A
Declines
ODDS (%)
Bearish Trend 8 days ago
87%
N/A
BollingerBands
ODDS (%)
N/A
N/A
Aroon
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
80%
View a ticker or compare two or three
Interact to see
Advertisement
LYRA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SQZB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
ACXP0.450.02
+4.27%
Acurx Pharmaceuticals
EYPT10.300.24
+2.39%
EyePoint Pharmaceuticals
APTV70.270.14
+0.20%
Aptiv PLC
BMA65.50-0.75
-1.13%
Banco Macro SA
MIST1.65-0.02
-1.20%
Milestone Pharmaceuticals

LYRA and

Correlation & Price change

A.I.dvisor indicates that over the last year, LYRA has been loosely correlated with EYPT. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if LYRA jumps, then EYPT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LYRA
1D Price
Change %
LYRA100%
+0.23%
EYPT - LYRA
58%
Loosely correlated
+2.39%
VERA - LYRA
54%
Loosely correlated
+0.85%
KYMR - LYRA
53%
Loosely correlated
+1.85%
BPMC - LYRA
42%
Loosely correlated
+0.14%
CLNN - LYRA
39%
Loosely correlated
+3.45%
More

SQZB and

Correlation & Price change

A.I.dvisor indicates that over the last year, SQZB has been loosely correlated with MDGL. These tickers have moved in lockstep 33% of the time. This A.I.-generated data suggests there is some statistical probability that if SQZB jumps, then MDGL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SQZB
1D Price
Change %
SQZB100%
N/A
MDGL - SQZB
33%
Loosely correlated
+1.09%
ARRY - SQZB
33%
Loosely correlated
-2.13%
AXON - SQZB
33%
Poorly correlated
+0.42%
MIST - SQZB
31%
Poorly correlated
-1.20%
LYRA - SQZB
29%
Poorly correlated
+0.23%
More